ERNA net incomeQ3 2026-$2.94M
ERNA net income was -$2.94M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.24M a year earlier. For the full fiscal 2025 it was -$14.08M, compared with -$44.54M in fiscal 2024.
Ernexa Therapeutics Inc. (ERNA) financials
For the twelve months ended Sep 30, 2026, Ernexa Therapeutics Inc. reported -$13.96M of net income.
- Net income, TTM
- -$13.96M
- Free cash flow, TTM
- -$10.75M
- Cash
- $5.58M
- Market cap
- $3.3M
FY2016FY2024
FY2016FY2025
FY2016FY2025
ERNA revenue and earnings growth
ERNA EPSQ3 2026-$1.89
ERNA diluted EPS was -$1.89 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$56.00.
ERNA free cash flowQ3 2026-$3.17M
ERNA free cash flow was -$3.17M in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$7.05M, compared with -$16.20M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $582.0K | $68.0K | $0 | - | $5.80M | $19.81M | $23.34M | $21.27M | $22.31M |
| Cost of revenue | - | $96.0K | $236.0K | $0 | - | - | - | - | - | - |
| Gross profit | - | $486.0K | -$168.0K | $0 | - | - | - | - | - | - |
| Research and development | $4.16M | $4.60M | $5.92M | $10.39M | $12.71M | $3.95M | $26.0K | $72.0K | $139.0K | - |
| Selling, general and admin | $5.16M | $13.13M | $14.59M | $16.84M | $14.72M | $3.30M | $13.18M | $14.46M | $15.59M | $16.46M |
| Operating income | -$9.32M | -$15.67M | -$21.14M | -$33.22M | -$113.73M | -$7.25M | -$1.76M | $203.0K | -$1.40M | -$2.28M |
| Interest expense | -$100.0K | -$6.80M | $500.0K | $30.0K | - | - | - | - | - | - |
| Pre-tax income | -$14.13M | -$44.51M | -$21.67M | -$24.53M | -$122.48M | -$7.29M | -$2.02M | -$323.0K | -$1.01M | -$2.88M |
| Income tax | -$45.0K | $30.0K | -$3.0K | $45.0K | $64.0K | $0 | $27.0K | -$64.0K | $66.0K | $38.0K |
| Net income | -$14.08M | -$44.54M | -$21.67M | -$24.58M | -$122.55M | -$7.29M | -$2.05M | -$259.0K | -$1.08M | -$2.92M |
| EPS, basic | -$56.00 | -$1224.00 | -$1530.00 | -$3022.50 | -$21228.75 | -$3075.00 | -$5400.00 | -$750.00 | -$3375.00 | -$11550.00 |
| EPS, diluted | -$56.00 | -$1224.00 | -$1530.00 | -$3022.50 | -$21228.75 | -$3075.00 | -$5400.00 | -$750.00 | -$3375.00 | -$11550.00 |
| Diluted shares | 252,280 | 36,400 | 14,170.667 | 8,136 | 5,773.333 | 2,345.067 | 0.383 | 0.358 | 325.6 | 253.733 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.88M | $1.73M | $11.67M | $15.54M | $16.98M | $1.63M | $5.10M | $2.54M | $3.38M | $5.69M |
| Receivables | - | - | - | - | $684.0K | $0 | $1.20M | $1.14M | $714.0K | $928.0K |
| Current assets | $3.13M | $2.35M | $9.60M | $13.68M | $18.77M | $1.73M | $6.07M | $6.79M | $9.64M | $10.66M |
| Goodwill | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $696.0K | $667.0K | $1.00M | $937.0K |
| Total assets | $5.83M | $5.27M | $49.13M | $22.28M | $31.52M | $12.91M | $14.13M | $14.86M | $16.57M | $16.70M |
| Current liabilities | $3.11M | $2.94M | $6.57M | $7.65M | $3.68M | $3.13M | $6.09M | $4.02M | $10.75M | $6.64M |
| Short-term debt | - | - | - | - | - | $1.50M | $2.74M | $1.00M | $5.06M | $2.99M |
| Long-term debt | - | - | $6.77M | $0 | - | $532.0K | - | - | - | - |
| Total debt | - | - | $6.77M | $0 | - | $2.03M | - | $3.75M | $5.12M | $8.11M |
| Total liabilities | $3.43M | $3.57M | $46.90M | $10.17M | $6.02M | $5.25M | $9.03M | $7.95M | $11.03M | $12.63M |
| Shareholders' equity | $2.40M | $1.70M | $2.23M | $12.11M | $25.50M | $7.66M | $9.74M | $6.92M | $5.54M | $4.07M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.02M | -$15.84M | -$20.41M | -$20.98M | -$23.49M | -$8.10M | $2.74M | $1.36M | $549.0K | $23.0K |
| Capital expenditures | $37.0K | $369.0K | $19.0K | $297.0K | $154.0K | $39.0K | $128.0K | $648.0K | $728.0K | $427.0K |
| Free cash flow | -$7.05M | -$16.20M | -$20.43M | -$21.27M | -$23.64M | -$8.14M | $2.62M | $717.0K | -$179.0K | -$404.0K |
| Investing cash flow | -$37.0K | -$365.0K | -$19.0K | -$47.0K | -$22.74M | -$39.0K | -$1.06M | -$1.58M | -$1.45M | -$840.0K |
| Financing cash flow | $7.21M | $6.26M | $16.56M | $19.58M | $61.59M | $4.67M | -$1.10M | -$303.0K | -$1.47M | $3.26M |
| Stock-based compensation | $1.50M | $1.52M | $1.24M | $2.94M | $5.24M | $91.0K | $206.0K | $443.0K | $457.0K | $419.0K |
| Depreciation and amortization | $65.0K | $139.0K | $84.0K | $161.0K | $117.0K | $98.0K | $360.0K | $2.76M | $2.32M | $2.89M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | 755.9% | - | - | - | -70.7% | -15.1% | 9.7% | -4.7% | -9.0% |
| Gross margin | - | 83.5% | -247.1% | - | - | - | - | - | - | - |
| Operating margin | - | -2693.1% | -31080.9% | - | - | -125.0% | -8.9% | 0.9% | -6.6% | -10.2% |
| Net margin | - | -7652.7% | -31864.7% | - | - | -125.7% | -10.3% | -1.1% | -5.1% | -13.1% |
| Free cash flow margin | - | -2784.4% | -30039.7% | - | - | -140.3% | 13.2% | 3.1% | -0.8% | -1.8% |
| Return on equity | -586.6% | -2618.4% | -970.4% | -203.0% | -480.5% | -95.2% | -21.0% | -3.7% | -19.5% | -71.9% |
| Return on assets | -241.4% | -845.3% | -44.1% | -110.3% | -388.7% | -56.5% | -14.5% | -1.7% | -6.5% | -17.5% |
| Current ratio | 1.01 | 0.80 | 1.46 | 1.79 | 5.10 | 0.55 | 1.00 | 1.69 | 0.90 | 1.60 |
| Debt to equity | - | - | 3.03 | 0.00 | - | 0.27 | - | 0.54 | 0.93 | 1.99 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $1.0K | $487.0K | $47.0K | $47.0K | $17.0K |
| Cost of revenue | $0 | $0 | $0 | - | $0 | $0 | $0 | $0 | -$60.0K | $95.0K | $61.0K | $66.0K |
| Gross profit | - | - | - | - | - | - | - | $1.0K | $547.0K | -$48.0K | -$14.0K | -$49.0K |
| Research and development | $1.87M | $2.79M | $1.92M | $676.0K | $1.03M | $1.14M | $1.31M | $1.16M | $1.00M | $987.0K | $1.46M | $1.36M |
| Selling, general and admin | $1.12M | $1.31M | $1.63M | $1.42M | $958.0K | $1.36M | $1.42M | $1.54M | $3.38M | $3.90M | $4.32M | $4.36M |
| Operating income | -$2.99M | -$4.10M | -$5.59M | -$2.09M | -$1.99M | -$2.50M | -$2.73M | -$2.70M | -$2.26M | -$4.93M | -$5.79M | -$5.76M |
| Interest expense | - | - | - | - | - | - | $800.0K | -$10.10M | $1.70M | $800.0K | $100.0K | - |
| Pre-tax income | -$2.94M | -$4.01M | -$5.55M | -$1.56M | -$1.23M | -$3.14M | -$8.19M | -$5.75M | -$26.59M | -$5.53M | -$6.64M | -$6.16M |
| Income tax | $0 | $0 | -$40.0K | -$62.0K | $6.0K | $3.0K | $8.0K | $11.0K | $12.0K | $3.0K | $4.0K | -$4.0K |
| Net income | -$2.94M | -$4.01M | -$5.51M | -$1.50M | -$1.24M | -$3.14M | -$8.20M | -$5.76M | -$26.60M | -$5.53M | -$6.65M | -$6.15M |
| EPS, basic | -$1.89 | -$3.40 | -$173.75 | - | -$3.77 | -$15.19 | -$1444.00 | - | -$1842.50 | -$383.50 | -$461.25 | -$427.50 |
| EPS, diluted | -$1.89 | -$3.40 | -$173.75 | - | -$3.77 | -$15.19 | -$1444.00 | - | -$1842.50 | -$383.50 | -$461.25 | -$427.50 |
| Diluted shares | 1.6M | 1.2M | 31,680 | - | 329,000 | 207,000 | 5,680 | - | 14,440 | 14,440 | 14,426.667 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.58M | $5.03M | $9.18M | $1.88M | $3.05M | $4.32M | $1.92M | $1.73M | $4.26M | $2.59M | $5.12M | $11.67M |
| Current assets | $6.73M | $5.89M | $10.00M | $3.13M | $3.38M | $4.79M | $2.21M | $2.35M | $4.73M | $3.58M | $6.16M | $9.60M |
| Goodwill | - | - | - | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M |
| Total assets | $7.10M | $6.32M | $10.54M | $5.83M | $6.17M | $7.58M | $5.06M | $5.27M | $7.72M | $46.49M | $49.66M | $49.13M |
| Current liabilities | $2.61M | $2.93M | $3.46M | $3.11M | $2.14M | $2.65M | $10.44M | $2.94M | $9.95M | $9.60M | $7.77M | $6.57M |
| Long-term debt | - | - | - | - | - | - | - | - | $32.04M | $8.89M | $8.01M | $6.77M |
| Total debt | - | - | - | - | - | - | - | - | $32.04M | $8.89M | $8.01M | $6.77M |
| Total liabilities | $2.75M | $3.12M | $3.68M | $3.43M | $2.60M | $3.14M | $11.01M | $3.57M | $53.11M | $55.01M | $53.07M | $46.90M |
| Shareholders' equity | $4.35M | $3.20M | $6.86M | $2.40M | $3.57M | $4.44M | -$5.95M | $1.70M | -$45.39M | -$8.53M | -$3.41M | $2.23M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.17M | -$4.15M | -$2.26M | -$1.15M | -$1.27M | -$2.53M | -$2.06M | -$3.54M | -$6.29M | -$2.26M | -$3.75M | -$4.66M |
| Capital expenditures | $0 | $3.0K | $2.0K | $15.0K | - | - | - | $0 | $19.0K | $249.0K | $101.0K | $19.0K |
| Free cash flow | -$3.17M | -$4.16M | -$2.27M | -$1.16M | - | - | - | -$3.54M | -$6.30M | -$2.51M | -$3.85M | -$4.68M |
| Investing cash flow | $0 | -$3.0K | -$2.0K | -$15.0K | - | - | - | $0 | -$19.0K | -$249.0K | -$97.0K | -$19.0K |
| Financing cash flow | $3.72M | $6.0K | $9.56M | $0 | $26.0K | $4.93M | $2.25M | $1.01M | $3.89M | -$22.0K | $1.39M | $7.70M |
| Stock-based compensation | $375.0K | $320.0K | $309.0K | $333.0K | $293.0K | $368.0K | $502.0K | $410.0K | $405.0K | $423.0K | $282.0K | $165.0K |
| Depreciation and amortization | $100.0K | $100.0K | $8.0K | $13.0K | $0 | $500.0K | $18.0K | $19.0K | $100.0K | $100.0K | $39.0K | $22.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | -94.1% | 854.9% | - | - | - |
| Gross margin | - | - | - | - | - | - | - | 100.0% | 112.3% | -102.1% | -29.8% | -288.2% |
| Operating margin | - | - | - | - | - | - | - | -269700.0% | -463.9% | -10491.5% | -12312.8% | -33911.8% |
| Net margin | - | - | - | - | - | - | - | -575900.0% | -5462.8% | -11763.8% | -14142.6% | -36194.1% |
| Free cash flow margin | - | - | - | - | - | - | - | -354500.0% | -1294.5% | -5336.2% | -8187.2% | -27529.4% |
| Current ratio | 2.57 | 2.01 | 2.89 | 1.01 | 1.58 | 1.81 | 0.21 | 0.80 | 0.48 | 0.37 | 0.79 | 1.46 |
| Debt to equity | - | - | - | - | - | - | - | - | - | - | - | 3.03 |
Source: XBRL data Ernexa Therapeutics Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Nov 14, 2022; 1-for-15, first reported Aug 13, 2025; 1-for-25, first reported Aug 6, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ERNA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ERNA | - | - | -$13.96M | - | $3.3M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
ERNA FAQ
5 questionsIs ERNA profitable?
No. Ernexa Therapeutics Inc. reported a net loss of $13.96M for the twelve months ended Sep 30, 2026.How much cash and debt does ERNA have?
Ernexa Therapeutics Inc. reported $5.58M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ERNA free cash flow?
Ernexa Therapeutics Inc. generated -$10.75M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$10.73M less capital expenditures.When did ERNA last report financial results?
The latest statements here come from Ernexa Therapeutics Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.Where does this ERNA financial data come from?
Quantisnow builds these statements from the structured XBRL data Ernexa Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.